Protein Inhibitors - CCT196969 (CAS: 1163719-56-9)

CCT196969 (CAS: 1163719-56-9)

Catalog #：EBC51026

Biological Activity

Synonyms

CCT196969; CCT-196969; CCT 196969

Chemical Name

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea

Application

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity

CAS Number

1163719-56-9

Purity

≥99.70%

Molecular Weight

513.52

Molecular Formula

C27H24FN7O3

SMILES

FC1=CC(OC2=C3C(NC(C=N3)=O)=NC=C2)=CC=C1NC(NC4=CC(C(C)(C)C)=NN4C5=CC=CC=C5)=O

Target & IC50

CRAF: IC50 = 0.01 μM
LCK: IC50 = 0.02 μM
Src: IC50 = 0.03 μM
BRAF: IC50 = 0.1 μM

Shipping

Gel Pack

Storage

Store at -20°C

Preparing Stock Solutions

Molecular Structure

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	1.9473 ml	9.7367 ml	19.4734 ml
5 mM	0.3895 ml	1.9473 ml	3.8947 ml
10 mM	0.1947 ml	0.9737 ml	1.9473 ml
50 mM	0.0389 ml	0.1947 ml	0.3895 ml

Solubility
DMSO: 100 mg/mL (194.73 mM)

Product Description

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. CCT196969 blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEKÂ–ERK, in vitro and in vivo. CCT196969 also prevented growth of xenografts derived from patient tumours with acquired or intrinsic resistance to BRAF and MEK inhibitors. BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs.